CA2143070A1 - Oral controlled release liquid suspension pharmaceutical formulation - Google Patents
Oral controlled release liquid suspension pharmaceutical formulationInfo
- Publication number
- CA2143070A1 CA2143070A1 CA 2143070 CA2143070A CA2143070A1 CA 2143070 A1 CA2143070 A1 CA 2143070A1 CA 2143070 CA2143070 CA 2143070 CA 2143070 A CA2143070 A CA 2143070A CA 2143070 A1 CA2143070 A1 CA 2143070A1
- Authority
- CA
- Canada
- Prior art keywords
- oil
- liquid suspension
- cellulose
- combinations
- controlled release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006194 liquid suspension Substances 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 abstract 3
- 235000006708 antioxidants Nutrition 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 3
- -1 hydroxypropyl-ethyl Chemical group 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000000648 anti-parkinson Effects 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000000939 antiparkinson agent Substances 0.000 abstract 2
- 229920001400 block copolymer Polymers 0.000 abstract 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract 2
- 239000008157 edible vegetable oil Substances 0.000 abstract 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003921 oil Substances 0.000 abstract 2
- 235000019198 oils Nutrition 0.000 abstract 2
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004380 Cholic acid Substances 0.000 abstract 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005642 Oleic acid Substances 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002873 Polyethylenimine Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 235000019486 Sunflower oil Nutrition 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 229920002988 biodegradable polymer Polymers 0.000 abstract 1
- 239000004621 biodegradable polymer Substances 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 235000019416 cholic acid Nutrition 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 229960002471 cholic acid Drugs 0.000 abstract 1
- 239000003240 coconut oil Substances 0.000 abstract 1
- 235000019864 coconut oil Nutrition 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229960003964 deoxycholic acid Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 229960002969 oleic acid Drugs 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 239000002600 sunflower oil Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A controlled release oral formulation for use with a variety of drugs, e.g. anti-Parkinsonian, cardiovascular and anti-epileptic drugs are formed in liquid suspension form. The ingredients in the suspension are water, an edible oil and a stabilizer for the liquid suspension, at least one pharmaceutically active ingredient, at least two water soluble biodegradable polymers, and optionally with at least one antioxidant to prevent degradation and oxidation of the pharmaceutically active ingredients. Suitable polymers are polysucrose, copolymer of sucrose and epichlorohydrin, hydroxyethyl cellulose hydroxypropyl-ethyl cellulose, hydoxypropyl-methyl cellulose, gelatine, starch, modified crosslinked starch, polyethyleneimine, methoxypolyethylene glycol, polyethylene oxide, cellulose acetate, polyvinyl alcohol, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene, block copolymers of polyoxypropylene, a mixture of hydroxyethyl cellulose and sodium carboxymethyl cellulose, and combinations thereof. Suitable edible oils are mineral oil, soyabean oil, coconut oil, vegetable oil and sunflower oil and combinations thereof. Suitable stabilizers are oleic acid, cholic acid, deoxycholic acid, pharmaceutically acceptable salts thereof and combinations thereof.
Suitable antioxidants are tocopherol, deteroxime mesylate, methyl paraben and ascorbic acid.
A typical teaspoon dose of anti-Parkinson liquid suspension contains 15-150 mg carbidopa, 50-1500 mg levodopa, 100-300 mg of a combination of polyvinyl alcohol and polysucrose, 10-50 mg oil, 5-15 mg antioxidant, e.g. vitamin E, 5-20 mg stabilizer, 10-15 mg colorants, 10-15 mg natural flavouring agents and 5 ml water.
Suitable antioxidants are tocopherol, deteroxime mesylate, methyl paraben and ascorbic acid.
A typical teaspoon dose of anti-Parkinson liquid suspension contains 15-150 mg carbidopa, 50-1500 mg levodopa, 100-300 mg of a combination of polyvinyl alcohol and polysucrose, 10-50 mg oil, 5-15 mg antioxidant, e.g. vitamin E, 5-20 mg stabilizer, 10-15 mg colorants, 10-15 mg natural flavouring agents and 5 ml water.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19993394A | 1994-02-22 | 1994-02-22 | |
| US08/199,933 | 1994-02-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2143070A1 true CA2143070A1 (en) | 1995-08-23 |
| CA2143070C CA2143070C (en) | 2001-12-18 |
Family
ID=22739620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2143070 Expired - Lifetime CA2143070C (en) | 1994-02-22 | 1995-02-21 | Oral controlled release liquid suspension pharmaceutical formulation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2143070C (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003670A1 (en) * | 1995-07-20 | 1997-02-06 | Smithkline Beecham P.L.C. | Paroxetine controlled release compositions |
| US5874447A (en) * | 1997-06-10 | 1999-02-23 | Synthon B. V. | 4-Phenylpiperidine compounds for treating depression |
| WO2000021521A2 (en) * | 1998-10-13 | 2000-04-20 | Pfizer Products Inc. | Sertraline oral concentrate |
| US6063927A (en) * | 1998-07-02 | 2000-05-16 | Smithkline Beecham Plc | Paroxetine derivatives |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| RU2678839C2 (en) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Compositions for continuous administration of dopa-decarboxylase inhibitors |
| US10624839B2 (en) | 2014-03-13 | 2020-04-21 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
| US10813902B2 (en) | 2014-03-13 | 2020-10-27 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622942A (en) * | 2013-11-04 | 2014-03-12 | 江苏大学 | Levodopa/carbidopa compound sustained-release suspension and preparation method thereof |
-
1995
- 1995-02-21 CA CA 2143070 patent/CA2143070C/en not_active Expired - Lifetime
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003670A1 (en) * | 1995-07-20 | 1997-02-06 | Smithkline Beecham P.L.C. | Paroxetine controlled release compositions |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US7229640B2 (en) | 1995-07-20 | 2007-06-12 | Smithkline Beecham P.L.C. | Paroxetine controlled release compositions |
| EP1382337A1 (en) * | 1995-07-20 | 2004-01-21 | Smithkline Beecham Plc | Novel formulation containing paroxetine |
| US6900327B2 (en) | 1997-06-10 | 2005-05-31 | Synthon Bct Technologies, Llc | 4-phenylpiperidine compounds |
| US5874447A (en) * | 1997-06-10 | 1999-02-23 | Synthon B. V. | 4-Phenylpiperidine compounds for treating depression |
| US7598271B1 (en) | 1997-06-10 | 2009-10-06 | Noven Therapeutics, Llc | Crystalline paroxetine methane sulfonate |
| US6063927A (en) * | 1998-07-02 | 2000-05-16 | Smithkline Beecham Plc | Paroxetine derivatives |
| US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
| AU766202B2 (en) * | 1998-10-13 | 2003-10-09 | Pfizer Products Inc. | Sertraline oral concentrate |
| WO2000021521A3 (en) * | 1998-10-13 | 2000-07-20 | Pfizer Prod Inc | Sertraline oral concentrate |
| WO2000021521A2 (en) * | 1998-10-13 | 2000-04-20 | Pfizer Products Inc. | Sertraline oral concentrate |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| RU2678839C2 (en) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Compositions for continuous administration of dopa-decarboxylase inhibitors |
| US10624839B2 (en) | 2014-03-13 | 2020-04-21 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
| US10813902B2 (en) | 2014-03-13 | 2020-10-27 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| CN107847722A (en) * | 2015-05-06 | 2018-03-27 | 辛纳吉勒公司 | Acceptable suspensions comprising drug particle, for the device of its dispensing and its application method |
| US10300033B2 (en) | 2015-05-06 | 2019-05-28 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10328044B2 (en) | 2015-05-06 | 2019-06-25 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10588882B2 (en) | 2015-05-06 | 2020-03-17 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| EP3291872A4 (en) * | 2015-05-06 | 2019-02-13 | SynAgile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10786474B2 (en) | 2015-05-06 | 2020-09-29 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US11135191B2 (en) | 2015-05-06 | 2021-10-05 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
| US11426376B2 (en) | 2015-05-06 | 2022-08-30 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11458115B2 (en) | 2020-11-17 | 2022-10-04 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2143070C (en) | 2001-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2143070A1 (en) | Oral controlled release liquid suspension pharmaceutical formulation | |
| KR100666016B1 (en) | Formulation comprising testosteron undecanoate and castor oil | |
| KR100249469B1 (en) | Soft gelatin capsule shell composition | |
| KR930008955B1 (en) | Ethanol filled medicine for soft gel containing vitamins dietary supplementary foods | |
| ZA836582B (en) | Constant release rate solid oral dosage formulations of drugs having a pka7-10 and an aqueous solubility of 15-100g/ml water | |
| CA1312549C (en) | Instant oral-release capsule containing nifedipine | |
| KR910000655B1 (en) | Process for preparing type soft capsule | |
| KR880007051A (en) | Denture stabilizing composition | |
| RU2008105830A (en) | NON-SUSPENSIBLE, QUICKLY DISPERSABLE FILM FOR ORAL USE CONTAINING A NEUROLEPTIC | |
| DK0904064T3 (en) | Oral pharmaceutical preparations containing sex hormones | |
| EP0374359A3 (en) | Chewable, edible soft gelatin capsule | |
| RU2002135623A (en) | RECIPE BASED ON HEPARIN, GLUCOSAMINOGLICAN OR HEPARINOID AND APPLICATION OF THE RECIPE AND ITS BASIS | |
| CA2168732A1 (en) | Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution | |
| EP0966966A3 (en) | Nefazodone dosage form | |
| JP2003508434A5 (en) | ||
| EP1029539A1 (en) | Pharmaceutical filled hard capsules | |
| TNSN97134A1 (en) | TRIMEBUTINE FILM MALEATE TABLET | |
| EP1344523A1 (en) | Ibuprofen solution for hard gelatin capsules | |
| ES8800040A1 (en) | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | |
| EP1741344A3 (en) | Chewing gum including a liquid sorbitol/mannitol/glycerin blend | |
| US5626872A (en) | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation | |
| JPS6440423A (en) | Patch for mucosa in oral cavity | |
| JPS621925B2 (en) | ||
| KR900701263A (en) | Ophthalmic pharmaceutical composition comprising a water-soluble acid addition salt of ibopamine | |
| WO1999066902A8 (en) | Injectable pharmaceutical formulations of partricin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150223 |